BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 27551741)

  • 21. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
    Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
    J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Robust Immune Responses by CpG-ODN-Loaded Hollow Polymeric Nanoparticles for Antiviral and Vaccine Applications in Chickens.
    Lin SY; Yao BY; Hu CJ; Chen HW
    Int J Nanomedicine; 2020; 15():3303-3318. PubMed ID: 32494131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.
    Chen YF; Lin CW; Tsao YP; Chen SL
    J Virol; 2004 Feb; 78(3):1333-43. PubMed ID: 14722288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Linker Length and Antigen Density in Nanoparticle Peptide Vaccine.
    Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
    ACS Omega; 2019 Mar; 4(3):5547-5555. PubMed ID: 30972374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
    Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
    Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.
    Nembrini C; Stano A; Dane KY; Ballester M; van der Vlies AJ; Marsland BJ; Swartz MA; Hubbell JA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(44):E989-97. PubMed ID: 21969597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
    Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
    ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
    Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
    Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
    Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses.
    Flechtner JB; Cohane KP; Mehta S; Slusarewicz P; Leonard AK; Barber BH; Levey DL; Andjelic S
    J Immunol; 2006 Jul; 177(2):1017-27. PubMed ID: 16818758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
    Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
    Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective Delivery of Antigen-Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection.
    Choi B; Moon H; Hong SJ; Shin C; Do Y; Ryu S; Kang S
    ACS Nano; 2016 Aug; 10(8):7339-50. PubMed ID: 27390910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
    Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
    Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.